Skip to content Skip to footer
Ofatumumab: Benefits, Reviews, Info, Side Effects!
Rx Details
Ofatumumab
Arzerra, HuMax-CD20
Ofatumumab
Prescription
Drug
Drugs
Prescription Only
treatment of chronic lymphocytic leukemia, treatment of relapsing forms of multiple sclerosis, reduction in disease progression, reduction in relapse rates, targeted B-cell therapy, subcutaneous administration, potential for fewer side effects compared to traditional chemotherapy
Back Pain, Cough, Diarrhea, Fatigue, Fever, Headache, Infusion-Related Reactions, Nausea, Neutropenia, Rash, Upper Respiratory Tract Infection
Ofatumumab is a medication used primarily for the treatment of certain types of blood cancers, such as chronic lymphocytic leukemia (CLL), and for multiple sclerosis (MS). The dosage of ofatumumab can vary depending on the condition being treated and the specific treatment protocol. For chronic lymphocytic leukemia (CLL), ofatumumab is typically administered as an intravenous infusion. The dosing schedule often starts with an initial higher dose followed by lower maintenance doses. For example, an initial dose might be 300 mg, followed by subsequent doses of 1,000 mg weekly for a period, and then monthly. For multiple sclerosis (MS), ofatumumab is administered as a subcutaneous injection. The typical dosing regimen for MS involves an initial loading dose of 20 mg given at weeks 0, 1, and 2, followed by a maintenance dose of 20 mg every four weeks. It’s important to note that the exact dosage and schedule should be determined by a healthcare professional based on the individual patient’s condition and response to treatment. Always consult with a healthcare provider for specific dosing recommendations.
Chronic lymphocytic leukemia, multiple sclerosis
Ofatumumab has a generally favorable safety profile.
No Interactions Reported
$1,000 – $5,000
$6,000 for a 20 mg/mL solution for injection.

A Synopsis of

Ofatumumab

Ofatumumab is a monoclonal antibody that is used in the treatment of certain types of blood cancers, such as chronic lymphocytic leukemia (CLL) and follicular lymphoma. It works by targeting a specific protein on the surface of cancer cells, which helps to slow down the growth and spread of the cancer.

This drug is typically given as an infusion in a medical setting, and the frequency and dosage will depend on the specific type of cancer being treated. It is important to follow your healthcare provider’s instructions carefully and attend all scheduled appointments to ensure the best possible outcome.

Like all medications, Ofatumumab can cause side effects. Some common side effects may include infusion reactions, low blood cell counts, and increased risk of infections. It is important to report any side effects to your healthcare provider so they can be properly managed.

Before starting treatment with Ofatumumab, it is important to discuss your medical history and any other medications or supplements you are taking with your healthcare provider. They will be able to determine if this drug is the right choice for you and monitor your progress throughout treatment.

Overall, Ofatumumab can be an effective treatment option for certain types of blood cancers. By working closely with your healthcare team and following their guidance, you can help manage your condition and improve your quality of life.

RxDb Legal Disclaimer

The information provided on RxDB.net is for informational purposes only and is not intended to replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional, such as a doctor or pharmacist, for any questions or concerns regarding your health, medications, or medical conditions. Reliance on any information provided on this website is solely at your own risk. RxDB.net does not provide medical or pharmaceutical services and is not liable for any decisions made based on the information contained herein.

PAGE LAST UPDATED

Health Education Through Aggregation

Sign up for the Rx Database Newsletter!
Menu
Questions?

Website By Foxco © 2025. All rights reserved.

0
Would love your thoughts, please comment.x
()
x
en_USEN